In patients with COPD, reduced IGF-1 levels in skeletal muscles led to decreased muscle protein synthesis by inhibiting the muscle hypertrophy pathway IGF-1-phosphoinositide 3-kinase-protein kinase B (Akt) [15,69]. Here, IGF1 is linked to chronic obstructive pulmonary disease.